259 related articles for article (PubMed ID: 36342807)
1. Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging.
Xie F; Fu L; Zhou W
Clin Nucl Med; 2022 Dec; 47(12):e758-e759. PubMed ID: 36342807
[TBL] [Abstract][Full Text] [Related]
2. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
[TBL] [Abstract][Full Text] [Related]
3. A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers.
Zang J; Lin R; Wen X; Wang C; Zhao T; Jakobsson V; Yang Y; Wu X; Guo Z; Chen X; Zhang J; Miao W
Clin Nucl Med; 2023 Oct; 48(10):861-868. PubMed ID: 37682601
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Imaging of Pancreatic Cancer With Liver Metastases.
Deng M; Chen Y; Cai L
Clin Nucl Med; 2021 Jul; 46(7):589-591. PubMed ID: 33630809
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT and 68Ga-FAPI-4 PET/CT Findings of Bilateral Knee Osteoarthritis in a Patient With Uveal Malignant Melanoma.
Erol Fenercioğlu Ö; Beyhan E; Ergül N; Arslan E; Çermik TF
Clin Nucl Med; 2022 Feb; 47(2):e144-e146. PubMed ID: 34319962
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Silini EM; Ruffini L
Clin Nucl Med; 2021 Sep; 46(9):e458-e460. PubMed ID: 34374683
[TBL] [Abstract][Full Text] [Related]
7. The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.
Shu Q; Deng M; Hu M; Liu M; Chen X; Chen Y; Cai L
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1442-1452. PubMed ID: 36609606
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
Cheng Z; Zou S; Cheng S; Song S; Zhu X
Clin Nucl Med; 2021 Sep; 46(9):764-765. PubMed ID: 34132674
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma.
Guo C; Liu Y; Yang H; Xia Y; Li X; Chen L; Feng Y; Zhang Y; Chen Y; Huang Z
Br J Radiol; 2024 Mar; 97(1156):859-867. PubMed ID: 38290775
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
[TBL] [Abstract][Full Text] [Related]
11. Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience.
Elboga U; Sahin E; Cayirli YB; Okuyan M; Aktas G; Haydaroglu Sahin H; Dogan I; Kus T; Akkurd DM; Cimen U; Mumcu V; Kilbas B; Celen YZ
Tomography; 2022 Feb; 8(1):293-302. PubMed ID: 35202189
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in the staging and restaging of gastric adenocarcinoma.
Gündoğan C; Kömek H; Can C; Yildirim ÖA; Kaplan İ; Erdur E; Poyraz K; Güzel Y; Oruç Z; Çakabay B
Nucl Med Commun; 2022 Jan; 43(1):64-72. PubMed ID: 34661379
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi Sarcoma.
Tatar G; Beyhan E; Erol Fenercioğlu Ö; Arslan E; Çermik TF
Clin Nucl Med; 2022 Sep; 47(9):e596-e599. PubMed ID: 35930714
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in Dermatofibrosarcoma Protuberans.
Wu J; Zhang S; Rao Z; Wang Y; Zhang C
Clin Nucl Med; 2022 Jul; 47(7):629-631. PubMed ID: 35452009
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell Carcinoma.
Pang Y; Wei J; Shang Q; Zhao L; Chen H
Clin Nucl Med; 2021 Feb; 46(2):177-179. PubMed ID: 33315682
[TBL] [Abstract][Full Text] [Related]
16. 68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT in Metastatic Papillary Renal Cell Cancer.
Civan C; Isik EG; Karadogan S; Sanli Y; Kuyumcu S
Clin Nucl Med; 2023 May; 48(5):e223-e224. PubMed ID: 36754359
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-FAPI PET/CT Detected Non-FDG-Avid Gastric Stromal Tumor.
Qiu L; Lan L; Liu H; Deng J; Chen Y
Clin Nucl Med; 2022 Mar; 47(3):226-227. PubMed ID: 34392281
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT in Patients With SAPHO Syndrome.
Wang P; Li C; Hou G; Li Z; Jing H; Zhang W; Li F
Clin Nucl Med; 2023 Sep; 48(9):781-784. PubMed ID: 37543757
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT of Chromophobe Renal Cell Carcinoma With Sarcomatoid Differentiation.
Lee CH; Kesari V; Legesse T; Chen W
Clin Nucl Med; 2018 May; 43(5):367-369. PubMed ID: 29485439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
